Chenguang Biotech Group Co., Ltd. Class A

Chenguang Biotech Group Co., Ltd. Class A

SSZSE:300138
12.49
CNY
+0.09
(+0.73%)
0.71EPS
16.05P/E
5.39BMarket Cap
Mar 30Next Earn

Total Valuation

CNY

As of September 30, 2026, Chenguang Biotech Group Co., Ltd. Class A carries a market capitalization of 5.39B, placing it among publicly traded companies globally. Its enterprise value stands at 6.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.39B
Enterprise Value6.60B

Important Dates

Chenguang Biotech Group Co., Ltd. Class A's next confirmed earnings release is scheduled for March 30, 2027.

Earnings Date3/30/2027

Share Statistics

As of September 30, 2026, Chenguang Biotech Group Co., Ltd. Class A has 483.10M shares outstanding.

Shares Outstanding483.10M

Valuation Ratios

As of September 30, 2026, Chenguang Biotech Group Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 16.05. The price-to-sales ratio is 0.82, and the price-to-book ratio stands at 1.57.

PE Ratio16.05
PS Ratio0.82
PB Ratio1.57
P/TBV Ratio1.74

Enterprise Valuation

As of September 30, 2026, Chenguang Biotech Group Co., Ltd. Class A trades at an EV/EBITDA multiple of 16.77 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.01 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.77 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 6.60B versus a market cap of 5.39B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.01
EV / EBITDA16.77
EV / EBIT16.77

Financial Position

As of September 30, 2026, Chenguang Biotech Group Co., Ltd. Class A maintains a current ratio of 1.32, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 127.36, indicating elevated leverage, while an interest coverage ratio of 3.79 demonstrates adequate ability to service its debt obligations.

Current Ratio1.32
Quick Ratio0.64
Debt / Equity127.36
Debt / EBITDA11.26
Interest Coverage3.79

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 3.15M in revenue per employee across its workforce of 2,079.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee3.15M
Employee Count2,079.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Chenguang Biotech Group Co., Ltd. Class A recorded 50.67M in income tax expense. That works out to an effective tax rate of 12.91, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 392.41M, leaving 335.40M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax50.67M
Effective Tax Rate12.91

Stock Price Statistics

CNY

As of the close on November 17, 2026, Chenguang Biotech Group Co., Ltd. Class A's stock has declined approximately 3.63% over the past 52 weeks. The 50-day moving average sits at 11.97, while the 200-day moving average is 11.79.

52-Week Price Change-3.63%
50-Day Moving Average11.97
200-Day Moving Average11.79

Income Statement

CNY

Over the twelve months ended September 30, 2026, Chenguang Biotech Group Co., Ltd. Class A generated 6.54B in revenue and converted that into 335.40M in net income, yielding earnings per share of 0.71. EBITDA reached 393.68M, while operating income came in at 490.38M.

Revenue6.54B
Gross Profit793.15M
Operating Income490.38M
Pretax Income392.41M
Net Income335.40M
EBITDA393.68M
EBIT393.68M
Earnings Per Share (EPS)0.71

Balance Sheet

CNY

As of September 30, 2026, Chenguang Biotech Group Co., Ltd. Class A holds 3.27B in cash and equivalents against 4.43B in total debt, resulting in a net debt position of 1.54B. Total book value stands at 3.42B, with working capital of 1.64B providing operational flexibility.

Cash & Cash Equivalents3.27B
Total Debt4.43B
Net Debt1.54B
Equity (Book Value)3.42B
Book Value Per Share7.08
Working Capital1.64B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-154.03M

Margins

Over the twelve months ended September 30, 2026, Chenguang Biotech Group Co., Ltd. Class A posted a gross margin of 12.12, reflecting its pricing power and cost economics. The operating margin of 7.49 and net profit margin of 5.13 provide insight into operational efficiency.

Gross Margin12.12
Operating Margin7.49
Pretax Margin6.00
Profit Margin5.13
EBITDA Margin6.02

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Chenguang Biotech Group Co., Ltd. Class A paid dividends of 0.52 per share. The dividend payout ratio of 71.67 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -5.26, meaning Chenguang Biotech Group Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.52
Payout Ratio71.67
Shareholder Yield-5.26

Stock Splits

Chenguang Biotech Group Co., Ltd. Class A's most recent stock split took place on June 27, 2018 with a 5:7 split ratio.

Last Split Date6/27/2018
Split Ratio5:7

Scores

As of September 30, 2026, Chenguang Biotech Group Co., Ltd. Class A has an Altman Z-Score of 2.15, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.15